Navigation Links
XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
Date:3/20/2008

cal trials, two of which, atazanavir for HIV, and entecavir for Hepatitis B, are currently approved drugs."

Ron Bentsur, XTL's CEO commented: "We are excited about this licensing transaction with a motivated and capable partner such as Presidio. This transaction allows us to solidify our financial position by bringing in $4 million dollars in cash and eliminating the ongoing development expense of the Program, while preserving a significant share in the Program's future success. We believe that this transaction extends our financial resources well into Q1 2009, and provides us with a financial cushion as we head towards the completion and announcement of results from the Bicifadine Phase 2b study, expected in Q4 2008."

The Program focuses on the development of novel small molecule inhibitors against the Hepatitis C virus, and is presently in advanced stages of lead optimization. The current lead compounds target NS5A - a viral protein that is essential for viral production. NS5A is distinct from the protease and polymerase. The Program's lead compounds are highly potent inhibitors of viral replication in the replicon assay, which is known to have good correlation with clinical efficacy and is currently the leading method for preclinical testing of inhibitors of the Hepatitis C Virus.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ:

SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 The Council for ... prestigious 2015 Borlaug CAST Communication Award goes to ... Tuskegee University in Alabama. Award nominees must demonstrate ... presentations; and/or the use of television, radio, or ... areas. As a specialist in the field of ...
(Date:4/16/2015)... Portage Biotech Inc. ("Portage" or "the Company" )) (OTC ... announce that the Company will be presenting  at the ... held in London, UK . Portage,s ... James Mellon , a director of Portage, will provide ... at its subsidiaries, Portage Pharmaceuticals Ltd. ("PPL"), and Biohaven ...
(Date:4/16/2015)... , April 16, 2015 /CNW/ - Bioenterprise Corporation is ... newest office in Charlottetown , PEI.  ... Prince Edward Island ADAPT Council for the commercialization of ... forward to working with PEI ADAPT.  They have been ... more than a decade," explains Dave Smardon , ...
(Date:4/16/2015)... A new infographic compiles useful information ... institutions to learn how Apple’s new framework can change ... is ideal since Apple made Research Kit ... open-source framework for developing medical research apps that Apple ... researchers to collect secure clinical data and communicate via ...
Breaking Biology Technology:The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4Bioenterprise Corporation Expands into the Maritimes 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3
... 14, 2011 /PRNewswire-Asia/ -- Global Pharm Holdings Group, Inc. ... or the "Company"), a Shenzhen-based, leading vertically integrated pharmaceutical ... its subsidiaries in Anhui, Jilin, and Shandong provinces, today ... 31, 2010. Fiscal Year 2010 Highlights ...
... 14, 2011 ERT (Nasdaq: ERT ... and customizable medial devices to biopharmaceutical and healthcare ... new contracts with top tier pharmaceutical companies, totaling ... outcomes (ePRO) business. The company has been selected ...
... BEDMINSTER, N.J., April 14, 2011 QRxPharma Limited ... the United States Patent and Trademark Office (USPTO) issued ... expires in 2029. This patent covers a proprietary dosing ... orally administered MoxDuo IR, thereby more effectively and safely ...
Cached Biology Technology:Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 2Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 3Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 4Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 5Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 6Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 7Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 8Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 9ERT Awarded over $10 Million of ePRO Business from Major Pharma - Increasing its Position as a Leading ePRO Provider 2ERT Awarded over $10 Million of ePRO Business from Major Pharma - Increasing its Position as a Leading ePRO Provider 3U.S. Patent and Trademark Office (USPTO) Issues QRxPharma a New Patent for MoxDuo® IR; Extends Patent Coverage to 2029 2U.S. Patent and Trademark Office (USPTO) Issues QRxPharma a New Patent for MoxDuo® IR; Extends Patent Coverage to 2029 3
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... trees, but energy could grow in grass. Researchers at ... geographic yield and economic analysis of potential bioenergy grass ... biofuels is increasing as Americans seek to expand renewable ... prices. Corn ethanol is the main biofuel on the ...
... 1, 2010) -- Imaging has rapidly become a ... But finding the right method and optimizing it ... for an established imaging laboratory. Cold Spring Harbor ... for detailed technical instruction for implementation of imaging methods ...
... danger and allowing us to spot prey, vision keeps many ... sense work, and why is it easier for us to ... than to notice other things? The complexity of the neural ... with a new technology and support from the National Science ...
Cached Biology News:Grasses have potential as alternate ethanol crop, Illinois study finds 2Grasses have potential as alternate ethanol crop, Illinois study finds 3Grasses have potential as alternate ethanol crop, Illinois study finds 4Imaging in depth: 3-dimensional microscopy featured in Cold Spring Harbor Protocols 2The zebrafish's neural circuit prevents it from biting off more than it can chew 2
... Reagents for the differentiation of mouse embryonic ... bodies exist in the midbrain, where they ... the ventral tegmental area, and the retrorubral ... to extensive forebrain dopamine innervation ( e.g.projections ...
... designed for RNA aptamer screening and binding ... powerful Paraflo microfluidic on-chip synthesis platform. Thousands ... synthesized on-chip and LC Sciences can provide ... are available as part of our comprehensive ...
... the C-terminal end of the mouse retinoic acid receptor beta (RAR*). ... of RAR*. The sequence of PEP-005 is (amino to carboxy terminus): ... S - S - V - E - N - S - ... L - L - Q (The N-terminal cysteine has been added ...
... ELx50 is a fast and versatile automated ... our patented Dual-ActionTM 16-channel manifold. This breakthrough ... dispense and aspiration manifolds for overfill washing ... 384-well formats. The problem of fitting dispense ...
Biology Products: